Verona Pharma

Lyra Therapeutics

Innoviva Inc

1999 PubMed publications found for Verona

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Evaluating the effectiveness of oral phlebotonics for the conservative management of hemorrhoidal disease: insights from the VIVI2022/01/VIVALDI study.

A pilot randomized controlled trial evaluating a resveratrol/β-glucan nasal spray for preventing respiratory symptoms in preschool children with recurrent wheezing.

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

In-Hospital Neonatal Head Injury: A Multicenter Retrospective Cohort Study.

2000 PubMed publications found for Verona

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

1997 PubMed publications found for Verona

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

1998 PubMed publications found for Verona

SW convergence: 50/100 (Neutral), 0 bullish / 1 bearish signals

1994 PubMed publications found for Verona

Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD.

1988 PubMed publications found for Verona

Identification and detection of genetic markers associated with antimicrobial susceptibility and evaluation of efflux pump mechanisms in Mycoplasma iowae.

Structure-Guided Evaluation of Thiol-Based Fluorescent Probes for Selective Detection and Inhibition of Metallo-β-Lactamases.

1986 PubMed publications found for Verona

Sexual Dysfunction with Antipsychotics: Emerging Clues from a Disproportionality Analysis of the World Health Organization VigiBase.

1985 PubMed publications found for Verona

1983 PubMed publications found for Verona

1982 PubMed publications found for Verona

The role of the molecular tumor board: learnings from the ROME trial.

1981 PubMed publications found for Verona

Safety and tolerability of the low global warming potential propellant HFA-152a in patients with asthma receiving beclometasone dipropionate/formoterol fumarate/glycopyrronium: The TRECOS study.

1980 PubMed publications found for Verona

1979 PubMed publications found for Verona

1978 PubMed publications found for Verona

1977 PubMed publications found for Verona

Failed, Inconclusive or Interrupted Trials in Multiple Sclerosis: 2020-2024 Update.

1976 PubMed publications found for Verona

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study.

<article class="bts-verified-summary" data-ticker="VRNA">
<p>Verona Pharma (VRNA) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 3 Phase 2<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>No Form 4 insider filings for VRNA were recorded at the SEC in the past 30 days<sup><a href="#fn-3">[3]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Verona+Pharma%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Verona+Pharma%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22VRNA%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR

Verona Pharma (VRNA) — BioTechSigns Verified Summary

Verona Pharma (VRNA) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[2], including 3 Phase 2[1].

No Form 4 insider filings for VRNA were recorded at the SEC in the past 30 days[3].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Verona+Pharma%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Verona+Pharma%22&aggFilters=status%3Arec%2Cact
[3] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22VRNA%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation. There are 7 in-clinic visits over a total duration of up to 24 weeks participation.

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).